Background/Aims: Endoscopic recurrence (ER) after intestinal resection for Crohn’s disease (CD) precedes the clinical recurrence, and the severity of ER correlates with the severity of the subsequent clinical recurrence. This study aimed to identify risk factors related to early ER after intestinal resection for CD and to create a prediction model. Methods: The patients who underwent intestinal resection for CD between April 2008 and April 2017 and took endoscopic evaluation between 6 and 12 months after surgery were retrospectively analyzed. Results: A total of 15 out of 52 (29%) patients developed early ER. A univariate analysis demonstrated that early ER was significantly correlated with history of prior intestinal resections for CD (p = 0.005), low preoperative albumin levels (p = 0.035), and excessive perioperative inflammation (i.e., high C-reactive protein levels in both preoperative and postoperative periods; p = 0.034). Based on these clinical factors, a nomogram for predicting early ER was created with the area under the curve 0.808. Conclusion: We developed a novel predictive nomogram for early ER after intestinal resection for CD. This prediction model might assist clinicians in managing patients with CD after an intestinal resection. Additional validation studies are currently being developed.

Journal Section:
Research Article
Keywords:
Crohn’s disease, Endoscopic recurrence, Prediction model, Nomogram
1.
Cones J, Gower-Rousseau C, Seksik P, Cortot A: Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology 2011; 140: 1785–1794.
2.
Yamamoto T: Factors affecting recurrence after surgery for Crohn’s disease. World J Gastroenterol 2005; 11: 3971–3979.
3.
Landsend E, Johnson E, Johannessen HO, Carlsen E: Long-term outcome after intestinal resection for Crohn’s disease. Scand J Gastroenterol 2006; 41: 1204–1208.
4.
Rutgeerts P, Geboes K, Vantrappen G, Kerremans R, Coenegrachts JL, Coremans G: Natural history of recurrent Crohn’s disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25: 665–672.
5.
Rutgeerts P, Geboes K, Vantrappen G, Beyls J, Kerremans R, Hiele M: Predictability of the postoperative course of Crohn’s disease. Gastroenterology 1990; 99: 956–963.
6.
Lochs H, Mayer M, Fleig WE, Mortensen PB, Bauer P, Genser D, et al: Prophylaxis of postoperative relapse in Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology 2000; 118: 264–273.
7.
Rutgeerts P, Van Assche G, Vermeire S, D’Haens G, Baert F, Noman M, et al: Ornidazole for prophylaxis of postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128: 856–861.
8.
de Barcelos IF, Kotze PG, Spinelli A, Suzuki Y, Teixeira FV, de Albuquerque IC, et al: Factors affecting the incidence of early endoscopic recurrence after ileocolonic resection for Crohn’s disease: a multicentre observational study. Colorectal Dis 2017; 19: 39–45.
9.
De Cruz P, Kamm MA, Hamilton AL, Ritchie KJ, Krejany EO, Gorelik A, et al: Crohn’s disease management after intestinal resection: a randomized trial. Lancet 2015; 11: 1406–1417.
10.
Monteiro S, Cúrdia Gonçalves T, Boal Carvalho P, Moreira MJ, Cotter J. Updating predictors of endoscopic recurrence after ileocolic resection for Crohn disease. Turk J Gastroenterol 2017; 28: 260–265.
11.
Ohara N, Mizushima T, Iijima H, Takahashi H, Hiyama S, Haraguchi N, et al: Adherence to an elemental diet for preventing postoperative recurrence of Crohn’s disease. Surg Today 2017; 47: 1519–1525.
12.
Miyoshi N, Ohue M, Yasui M, Noura S, Shingai T, Sugimura K, et al: Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection. ESMO Open 2016; 1:e000052.
13.
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et al: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541–1549.
14.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, et al: Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007; 132: 1672–1683.
15.
Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al: Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med 2013; 369: 711–721.
16.
Sandborn WJ, Gasink C, Gao LL, Blank MA, Johanns J, Guzzo C, et al: Ustekinumab induction and maintenance therapy in refractory Crohn’s disease. N Engl J Med 2012; 367: 1519–1528.
17.
Colvin H, Mizushima T, Eguchi H, Takiguchi S, Doki Y, Mori M: Gastroenterological surgery in Japan: the past, the present and the future. Ann Gastroenterol Surg 2017; 1: 5–10.
18.
Binder V, Hendriksen C, Kreiner S: Prognosis in Crohn’s disease – based on results from a regional patient group from the county of Copenhagen. Gut 1985; 26: 146–115.
19.
Gionchetti P, Dignass A, Danese S, Magro Dias FJ, Rogler G, Lakatos PL, et al: 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 2: surgical management and special situations. J Crohns Colitis 2017; 11: 135–149.
20.
McLeod RS, Wolff BG, Ross S, Parkes R, McKenzie M; Investigators of CAST Trial: Recurrence of Crohn’s disease after ileocolic resection is not affected by anastomotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum 2009; 52: 919–927.
21.
Gklavas A, Dellaportas D, Papaconstantinou I: Risk factors for postoperative recurrence of Crohn’s disease with emphasis on surgical predictors. Ann Gastroenterol 2017; 30: 598–612.
22.
Hellers G: Crohn’s disease in Stockholm county 1955–1974. A study of epidemiology, results of surgical treatment and long-term prognosis. Acta Chir Scand Suppl 1979; 490: 1–84.
23.
Wang H, Zuo L, Zhao J, Dong J, Li Y, Gu L, et al: Impact of preoperative exclusive enteral nutrition on postoperative complications and recurrence after bowel resection in patients with active Crohn’s disease. World J Surg 2016; 40: 1993–2000.
24.
Guo Z, Cao L, Guo F, Gong J, Li Y, Gu L, et al: The presence of postoperative infectious complications is associated with the risk of early postoperative clinical recurrence of Crohn’s disease. World J Surg 2017; 41: 2371–2377.
25.
Vermeire S, Van Assche G, Rutgeerts P: The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 580–586.
26.
Vermeire S, Van Assche G, Rutgeerts P: Laboratory markers in IBD: useful, magic, or unnecessary toys? Gut 2006; 55: 426–431.
27.
Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, et al: C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008; 57: 1518–1523.
28.
Kiss LS, Papp M, Lovasz BD, Vegh Z, Golovics PA, Janka E, et al: High-sensitivity C-reactive protein for identification of disease phenotype, active disease, and clinical relapses in Crohn’s disease: a marker for patient classification? Inflamm Bowel Dis 2012; 18: 1647–1654.
29.
Caprilli R, Corrao G, Taddei G, Tinelli F, Torchio P, Viscido A: Prognostic factors for postoperative recurrence of Crohn’s disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Dis Colon Rectum 1996; 39: 335–341.
30.
Laculli E, Agostini M, Biancone L, Fiorani C, Di Vizia A, Montagnese F, et al: C-reactive protein levels in the perioperative period as a predictive marker of endoscopic recurrence after ileo-colonic resection for Crohn’s disease. Cell Death Discov 2016; 2: 16032.
31.
Regueiro M, Schraut W, Baidoo L, Kip KE, Sepulveda AR, Pesci M, et al: Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology 2009; 136: 441–450.
32.
Savarino E, Bodini G, Dulbecco P, Assandri L, Bruzzone L, Mazza F, et al: Adalimumab is more effective than azathioprine and mesalamine at preventing postoperative recurrence of Crohn’s disease: a randomized controlled trial. Am J Gastroenterol 2013; 108: 1731–1742.
33.
Regueiro M, Feagan BG, Zou B, Johanns J, Blank MA, Chevrier M, et al: Infliximab reduces endoscopic, but not clinical, recurrence of Crohn’s disease after ileocolonic resection. Gastroenterology 2016; 150: 1568–1578.
34.
Polterauer S, Grimm C, Hofstetter G, Concin N, Natter C, Sturdza A, et al: Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer 2012; 107: 918–924.
35.
Kawai K, Ishihara S, Yamaguchi H, Sunami E, Kitayama J, Miyata H, et al: Nomogram prediction of metachronous colorectal neoplasms in patients with colorectal cancer. Ann Surg 2015; 261: 926–932.
36.
Lian L, Stocchi L, Shen B, Liu X, Ma J, Zhang B, et al: Prediction of need for surgery after endoscopic balloon dilation of ileocolic anastomotic stricture in patients with Crohn’s disease. Dis Colon Rectum 2015; 58: 423–430.
37.
Guizzetti L, Zou G, Khanna R, Dulai PS, Sandborn WJ, Jairath V, et al: Development of clinical prediction models for surgery and complications in Crohn’s disease. J Crohns Colitis 2018; 12: 167–177.
© 2019 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2019
You do not currently have access to this content.